Hereditary Angioedema (HAE)
Posters
Exploring the Quality of Life Benefits of Subcutaneous C1-Inhibitor (C1-INH) Replacement Therapy Using Qualitative Research Methods
Durability of Symptom Control with Long-term Prophylactic Therapy With Subcutaneous C1-Inhibitor in Patients With Hereditary Angioedema
Weight-based Dosing of Subcutaneous C1-Inhibitor Facilitates Management of Hereditary Angioedema in Obese Patients
Key Publications
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
Longhurst H, Cicardi M, Craig T, et al.
N Engl J Med 2017
Request | Ask a Question
Long-term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
Craig T, Zuraw B, Longhurst H, et al.
J Allergy Clin Immunol Pract 2019
Request | Ask a Question
Important Safety Information for HAEGARDA
HAEGARDA®, C1 Esterase Inhibitor Subcutaneous (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older. HAEGARDA is for subcutaneous use after reconstitution only.
HAEGARDA is contraindicated in patients with a history of life-threatening hypersensitivity reactions, including anaphylaxis, to C1-INH preparations or their excipients.
Severe hypersensitivity reactions to HAEGARDA could occur. In such cases, discontinue administration and institute appropriate treatment. Epinephrine should be immediately available to treat hypersensitivity reactions.
At the recommended subcutaneous dose of HAEGARDA, no causal relationship to thromboembolic events (TEs) has been established. However, TEs have been reported with intravenous administration of C1-INH products, usually at high doses.
In clinical trials, adverse reactions observed in more than 4% of subjects treated with HAEGARDA were injection-site reactions, hypersensitivity, nasopharyngitis, and dizziness.
HAEGARDA is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
Please see full prescribing information for HAEGARDA.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
